ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript
ADC Therapeutics SA misses on earnings expectations. Reported EPS is $-1.03 EPS, expectations were $-0.47.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Redmile Group Jeremy Green | 15,328,317 | $25,445,006 | +9% | 0.91% |
2. | Prosight Capital Lawrence Hawkins | 6,471,800 | $10,743,188 | +20% | 4.31% |
3. | Millennium Management Israel Englander | 2,672,810 | $4,436,865 | +1% | 0% |
4. | Citadel Investment Group Ken Griffin | 1,853,412 | $3,076,664 | -37% | 0% |
5. | Magnetar Capital Alec Litowitz And Ross Laser | 55,762 | $92,565 | 0% |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 1,525,741 | $2,532,730 | 0% | |
2. | 1,459,514 | $2,422,793 | 0% | |
3. | 1,013,540 | $1,682,476 | 0.3% | |
4. | 850,737 | $1,412,224 | 0.94% | |
5. | 781,937 | $1,298,016 | 0% |